Iterum Therapeutics’ (ITRM) Neutral Rating Reaffirmed at HC Wainwright

Iterum Therapeutics (NASDAQ:ITRM)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

Other analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Iterum Therapeutics in a research report on Monday, December 22nd. Maxim Group cut shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 4th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Iterum Therapeutics has an average rating of “Reduce” and a consensus target price of $9.00.

Iterum Therapeutics Price Performance

Shares of ITRM traded up $0.04 during mid-day trading on Monday, reaching $0.08. 706,762,164 shares of the company’s stock traded hands, compared to its average volume of 13,233,652. The stock’s 50-day moving average is $0.24 and its two-hundred day moving average is $0.43. Iterum Therapeutics has a 12 month low of $0.03 and a 12 month high of $1.42. The stock has a market cap of $4.08 million, a P/E ratio of -0.11 and a beta of 2.96.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in shares of Iterum Therapeutics during the third quarter valued at approximately $32,000. Jane Street Group LLC purchased a new position in shares of Iterum Therapeutics in the 2nd quarter valued at $92,000. OneDigital Investment Advisors LLC raised its position in shares of Iterum Therapeutics by 18.6% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after acquiring an additional 30,000 shares in the last quarter. Alchemi Wealth LLC purchased a new stake in shares of Iterum Therapeutics during the 4th quarter worth $90,000. Finally, Apollon Financial LLC boosted its position in Iterum Therapeutics by 151.8% during the fourth quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock valued at $211,000 after purchasing an additional 380,000 shares in the last quarter. Hedge funds and other institutional investors own 9.21% of the company’s stock.

About Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).